ABSTRACT Background: Broad-spectrum antibiotics are often used as initial empiric therapy in patients at risk for infections by multidrug-resistant organisms. Emerging literature and anecdotal reports within Tripler Army Medical Center indicate an increased incidence of vancomycin-associated acute kidney injury when used in combination with piperacillin-tazobactam. This is a retrospective, single-center study comparing the incidence of acute kidney injury in noncritically ill patients receiving either vancomycin or vancomycin in combination with piperacillin-tazobactam in a 206-bed tertiary care military training facility. Methods: Data were collected from electronic medical records between May 2012 and October 2014 and evaluated via multivariable logistic regression models. Patients included for analysis were 17 years of age and older, were admitted to medical/surgical wards, and received vancomycin or vancomycin in combination with piperacillin-tazobactam for at least 48 hours. A vancomycin trough level, baseline serum creatinine level, and at least two follow-up serum creatinine levels were required for inclusion. Patients were excluded if they were pregnant, admitted to an intensive care unit while on antimicrobial therapy, or their baseline serum creatinine was equal to or greater than 1.5 mg/dL. Results: Of 1,133 patients evaluated retrospectively, 455 were included for analysis. Of 202 patients, 49 (24%) taking vancomycin in combination with piperacillin-tazobactam developed acute kidney injury in contrast to 28 of the 253 patients (11%) given vancomycin without piperacillin-tazobactam (unadjusted odds ratio 2.57 [95% confidence interval (CI) 1.55-4.28], p < 0.001). Dual therapy remained significant after adjusting for age, sex, body mass index, concomitant nephrotoxic agents, and preexisting comorbid status as evaluated by Charlson comorbidity index (adjusted odds ratio 2.14 [95% CI 1.26-3.6], p = 0.005). Contrast administration ( p < 0.001), fluoroquinolone administration ( p < 0.001), and Charlson Comorbidity Index > 6 ( p = 0.008) were also found to be independent risk factors for acute kidney injury. Conclusion: Significant increased incidence of nephrotoxicity was noted with vancomycin and piperacillin-tazobactam as compared to vancomycin within Tripler Army Medical Center. This finding influenced our institution's decision to add ceftaroline as a formulary agent in the treatment of skin and soft-tissue infections and further supported the need for rapid de-escalation of antibiotics within our military training facility.
INTRODUCTION
Broad-spectrum antimicrobials are often used in a host of infections because of increasing concern for multidrugresistant organisms. Patients often empirically receive an antimicrobial targeted against gram-negative rods in addition to vancomycin. These medications not only provide empiric coverage of severe infections in hospitalized patients but also introduce the risk for adverse drug effects to include acute kidney injury (AKI). 1, 2 Vancomycin, a glycopeptide, was first introduced more than 50 years ago for gram-positive bacterial infections and is now a widely used treatment of methicillin-resistant Staphylococcus aureus. Recent studies report the incidence rate of nephrotoxicity from 12% to 19%, with differences dependent on dosing strategies and patient characteristics. 3 Administration variables associated with increased incidence of kidney injury include trough level greater than 15 mg/L and duration of therapy over at least 7 days. 3, 4 Intrinsic patient characteristics have also been found to affect the occurrence of nephrotoxicity. Obesity has been identified as an independent risk factor as volume of drug distribution does not increase proportionally to weight and can lead to a higher trough. In addition, intensive care unit (ICU) stay has been associated with increased rate of nephrotoxicity. 5 Another commonly cited risk factor is concomitant administration of known nephrotoxic agents. Specifically noted examples include aminoglycosides, amphotericin B, loop diuretics, vasopressors, and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). 1, 4, 6, 7 Emerging literature indicates an increased risk of AKI with the combination of vancomycin and piperacillin-tazobactam. 2, 8, 9 A recent retrospective study by Meaney et al found a 13.6% incidence of vancomycinassociated nephrotoxicity in 125 adult internal medicine patients with concomitant administration of piperacillintazobactam (odds ratio [OR] 5.36 [95% confidence interval (CI) 1.41-20.5], p = 0.014). 10 In a 2014 matched cohort study of 224 patients, 34.8% of patients receiving vancomycin and piperacillin-tazobactam developed AKI compared to only 12.5% of patients given vancomycin and cefepime ( p < 0.0001).
2 A 2014 single-center retrospective cohort study of 191 adult patients found an 8.1% incidence of nephrotoxicity with vancomycin administration without piperacillin-tazobactam as opposed to a 16.3% incidence in patients given vancomycin and piperacillin-tazobactam (onesided χ 2 test, p = 0.032, 95% CI > 1.11). 9 However, there has been recent literature that has not supported this increased incidence of nephrotoxicity with concomitant therapy. A retrospective cohort study of 139 patients given either vancomycin plus piperacillin-tazobactam or vancomycin plus cefepime found a 29.3% incidence of AKI with concomitant piperacillin-tazobactam administration as compared to 13.3% with vancomycin and cefepime administration, though statistical significance was not met ( p = 0.099).
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Also, a recent retrospective cohort study did not find a significant difference in nephrotoxicity after evaluating 530 patients on vancomycin, vancomycin and piperacillin-tazobactam, or vancomycin and other gram-negative rod antibiotics. 12 
OBJECTIVES
The purpose of this retrospective study was to identify the risk of developing AKI in patients with normal baseline kidney function admitted to a noncritical care ward and given vancomycin or vancomycin and piperacillin-tazobactam. Other risk factors for nephrotoxicity to include comorbidity status, high vancomycin trough goal, and concomitant nephrotoxic agent administration were likewise evaluated as secondary endpoints.
METHODS

Study Design and Setting
This study used retrospective data retrieved from electronic medical records of a 206-bed tertiary care military treatment facility. This project is a product of a research protocol approved by the Tripler Army Medical Center Institutional Review Board (Protocol Number 17R19). Investigators adhered to the policies for protection of human subjects as prescribed in 45 Code of Federal Regulation 46. The primary objective was to evaluate the incidence of nephrotoxicity in hospitalized adult patients with normal baseline kidney function who received intravenous (IV) vancomycin with and without concomitant administration of piperacillintazobactam. Secondary endpoints were to evaluate the incidence of nephrotoxicity in patients with the following risk factors: total vancomycin dosage of more than 4 g/day, vancomycin trough goal equal to or greater than 15 mg/L, concomitant nephrotoxic agent administration, and high comorbid status as evaluated by the Charlson Comorbidity Index (CCI).
Patient Selection and Data Collection
Hospital records from May 2012 through the end of October 2014 were reviewed to determine patients that were administered vancomycin and vancomycin with piperacillintazobactam. Patients in the vancomycin or vancomycin and piperacillin-tazobactam groups may have received other antibiotics concurrently. Patients evaluated were older than 17 years of age who received vancomycin or vancomycin and piperacillin-tazobactam for at least 48 hours. A baseline serum creatinine (SCr) level and at least two follow-up SCr levels were required for inclusion, with baseline SCr defined as the lowest level within 1 week of initiation of antibiotics. Patients were excluded if SCr was equal to or greater than 1.5 mg/dL, on hemodialysis, admitted to the ICU while on antimicrobial therapy, or pregnant.
Administration of vancomycin or piperacillin-tazobactam was individually assessed and verified on each patient through pharmacist progress notes on Essentris, the Defense Health Agency electronic health record system. Steady-state vancomycin trough level was defined as the level drawn 1 hour or less before administration of the fourth consecutive vancomycin dose and at least one level per patient was required. All SCr levels and vancomycin trough levels were obtained from Composite Health Care System (CHCS), the U.S. military health care center medical informatics system.
All patients on vancomycin were managed by a pharmacybased pharmacokinetics consult service and all doses of piperacillin-tazobactam were given as an extended infusion more than 4 hours at an every 8-hour interval. Demographic data were collected on eligible patients to include length of hospital stay, height, weight, hours on vancomycin, vancomycin target range, indication for vancomycin, average vancomycin trough levels, peak vancomycin trough levels, baseline SCr, peak SCr, discharge SCr, and if dose of vancomycin was greater than 4 g/day. Creatinine clearance using the Cockcroft-Gault equation (maximum rate at 120 mL/ min) was also calculated. Exposure to nephrotoxic agents was evaluated to include allopurinol, antivirals, aminoglycosides, amphotericin, nonsteroidal anti-inflammatory drugs (NSAIDs), ACE inhibitors or ARBs, loop diuretics, trimethoprim/ sulfamethoxazole, flouroquinolones, other beta-lactams, and administration of IV contrast. Comorbid conditions for each patient were obtained by searching for the patient International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) codes through CHCS and reviewed to calculate a CCI score for all patients. The term "noncritically ill patient" was defined as not requiring ICU admission during the interval of antibiotic administration. The primary outcome of AKI was characterized by the Acute Kidney Injury Network definition as an abrupt (within 48 hours) increase in SCr of ≥0.3 mg/dL or ≥ 50% from baseline.
Statistical Analysis A sample size of 400 patients (200 in each group) was estimated to be required for the study to have 80% power (α = 0.05) to detect a difference in AKI incidence rates of 10% and 21% between treatment groups. Two-sided Fisher's exact tests were used to evaluate associations between categorical variables and treatment group, and nonparametric Wilcoxon rank sum tests were used to compare associations between continuous variables and treatment group. Because patients were not randomly assigned to a treatment group, a propensity score from a logistic model to predict treatment group on the basis of treatment indication (joint infection/osteomyelitis or neutropenic fever) was estimated for each patient.
Multivariable logistic regression was used to assess whether incidence of AKI nephrotoxicity differed between the vancomycin and piperacillin-tazobactam groups, adjusted for the propensity score and potential risk factors identified using a stepwise modeling approach (0.10 to enter and 0.05 to remove). Demographic, baseline characteristic, and nephrotoxic agent variables were eligible for the adjusted model. A significance level of 0.05 was used for all analyses. All analyses were done using SAS statistical software, version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
In total, 1,133 patients were evaluated for inclusion. Of these, 678 were excluded as outlined in Table I ; 253 patients received vancomycin and 202 patients received vancomycin with piperacillin-tazobactam. The most common reasons for exclusion were administration of antibiotics for less than 48 hours and baseline SCr greater than 1.5 mg/dL. As shown in Table II , demographics and clinical characteristics of age, weight, body mass index, baseline SCr, average and peak vancomycin trough levels, and duration of therapy were not significantly different. The CCI, a marker of medical comorbidities, was found to be significantly higher in the group receiving vancomycin with piperacillin-tazobactam as opposed to vancomycin (mean CCI 4.4 [95% CI 3.9-4.9] vs. 3.8 [95% CI 3.3-4.3], p = 0.017).
As demonstrated in Table III , there was no statistical difference in the number of patients receiving more than 4 g of vancomycin and patients with a goal trough higher than 15 mg/L between the two groups. Of concomitant nephrotoxic medication administration, allopurinol and IV contrast were found to be given disproportionally to the combination group though there was no difference in usage of other agents. Meningitis, urinary tract infection, and neutropenic fever were more common in the vancomycin group, whereas joint infection/osteomyelitis was a more common treatment indication in the combination group. None of these treatment indications were independent risk factors for development of AKI. Unadjusted, the primary endpoint of incidence of AKI was found to be significantly associated with vancomycin in combination with piperacillin-tazobactam as 24% (49 of 202) of patients had nephrotoxicity compared to 11% (28 of 253) of patients in the vancomycin arm (OR 2.57 [95% CI 1.55-4.28], p < 0.001). Of the secondary endpoints evaluated, the CCI was found to be an independent risk factor for AKI (AKI incidence = 26%, 28/108 patients with CCI > 6, vs. 14%, 49/347 for patients with CCI ≤ 6, p = 0.008). Of the different comorbidities evaluated within the CCI, congestive heart failure, moderate-to-severe renal failure, and diabetes with evidence of end organ dysfunction were found to be independent risk factors for AKI. Contrast administration was also found to be strongly associated with developing AKI as 26% (42/162) of patients with contrast developed AKI compared to 12% (35/293) without contrast ( p < 0.001). Administration of fluoroquinolones was also found to be an independent risk factor as 23% (52/224) of patients administered this class of antibiotics developed AKI vs. 11% (25/231) who were not ( p < 0.001). However, goal trough over 15 mg/L and vancomycin dose over 4 g/day were not associated with increased risk of nephrotoxicity. After adjusting for independent risk factors of CCI, contrast administration, and fluoroquinolone administration, combination therapy was still associated with increased rate of AKI (adjusted OR 2.14 [95% CI 1.26-3.66], p = 0.005).
DISCUSSION
Despite the established correlation between vancomycin administration and nephrotoxicity, the mechanism by which kidney injury occurs is not well understood as most research thus far has been performed on animal models. Vancomycin is almost exclusively renally secreted, mainly via glomerular filtration with some active tubular secretion. 13 Other studies have suggested that vancomycin-induced kidney injury may be secondary to acute interstitial nephritis or to oxidative stress on cells of the proximal renal tubule.
14, 15 Oktem et al examined erdosteine, an expectorant agent with antioxidant properties, and found that it decreased reactive oxygen metabolites and led to marked reduction in tubular damage when given with vancomycin as compared to vancomycin alone. 15 Although it normally takes 3 to 5 days for acute interstitial nephritis to develop after exposure to an offending agent, we chose the exclusion cutoff of 48 hours on vancomycin since the cause of vancomycin nephrotoxicity can be multifactorial. The 17% overall incidence of nephrotoxicity noted in this analysis is comparable to other recent studies. In a study of 166 patients treated with vancomycin, 12% experienced nephrotoxicity with the median time to vancomycin toxicity of 6 days. In these patients, daily dosing of more than 4 g of vancomycin as well as initial trough level more than 9.9 mg/L was associated with a significantly higher incidence of nephrotoxicity. 5 Other studies have found increased incidence of AKI associated with trough levels more than 15 mg/L. 3, 4 Interestingly, our analysis showed no association between trough goal or vancomycin dose more than 4 g/day. A total of 16% of patients receiving more than 4 g developed AKI as opposed to 17% of patient's receiving a lower dose. Likewise, 17% of patient's targeted to more than 15 mg/L developed an AKI, which was the same rate as those targeted to lower trough. This could be the result of the shorter duration allowed in this study where patients may have received therapy for only 48 hours. The vancomycin levels and subsequent dosing were also managed by clinical pharmacy service and would have been adjusted and monitored regularly. Patients may have had fewer supratherapeutic levels than patients in previous studies.
Although piperacillin-tazobactam in monotherapy is a rarely implicated cause of nephrotoxicity, several recent studies have associated it with a higher instance of AKI when combined with vancomycin. 2, [8] [9] [10] Our study found results similar to these works, as 24% of patients taking vancomycin/piperacillin-tazobactam developed AKI in contrast to 11% given vancomycin (adjusted OR 2.14 [95% CI 1.26-3.66] p = 0.005). Only one of these studies specifically evaluated noncritically ill patients as our work did. 8 However, although this study evaluated for coadministration of IV contrast, aminoglycosides, NSAIDs, and Tenofovir, it did not evaluate for a plethora of other known nephrotoxic agents. It also did not account for many important comorbidities to include congestive heart failure, peripheral vascular disease, prior myocardial infarction, dementia, liver disease, chronic obstructive pulmonary disease, and connective tissue disease. It must be noted that several studies have not found a statistical difference in rates of nephrotoxicity between vancomycin and vancomycin with piperacillin-tazobactam administration. A retrospective cohort study of 530 patients treated with vancomycin, vancomycin with piperacillintazobactam, or vancomycin with alternative gram-negative rod antibiotics failed to find a significant difference in incidence of AKI between the groups. However, AKI in that study was defined as an increase in SCr of 0.5 mg/dL as opposed to 0.3 mg/dL, as used in our analysis. Also, ICU patients were included in the study. 12 A retrospective cohort study of 139 patients by Moenster et al comparing incidence of nephrotoxicity in patients with diabetes and osteomyelitis failed to find a significant difference in AKI between patients given vancomycin with piperacillin-tazobactam (29.3%) vs. vancomycin with cefepime (13.3%). However, this study was small and underpowered to demonstrate a statistical significance.
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Several important limitations in our analysis must be noted. There were multiple confounding factors inherent to the nature of this retrospective work although combination therapy was still associated with increased risk of AKI after adjustment for these confounding factors. We chose to exclude critically ill patients who often have multiple reasons for organ failure in an attempt to minimize confounding reasons for nephrotoxicity. Although critically ill patients were excluded, episodes of hypotension that may not have met criteria for ICU admission were not evaluated. This is important as an episode of hypotension may have led to the initial decision to initiate combination therapy, and likewise may have predisposed the patient to AKI. It was not surprising that patients with a higher number of comorbidities were found to be at increased risk of developing nephrotoxicity. Of note, the vancomycin with piperacillin-tazobactam group had a statistically higher CCI score compared to the vancomycin group, although after adjustment the addition of piperacillin-tazobactam was still an independent risk factor for nephrotoxicity.
A report from our electronic medical record was used to determine if patients had orders for nephrotoxic agents to include IV contrast during hospitalization. The report generated was not able to verify overlap of nephrotoxic agents administered with antibiotic therapy, only that at some point in the hospitalization it was ordered. Although contrast administration was an independent risk factor for AKI, as were high CCI score and fluoroquinolone administration, combination therapy was still associated with increased rate of AKI after adjustment.
Also, the comorbidities used in the CCI calculations were determined by evaluation of each patient's current ICD-9 codes. A patient may have developed a comorbid state used in the calculation subsequent to the hospitalization where they were administered the antibiotics. In addition, we excluded patients with baseline kidney dysfunction as defined by SCr > 1.5 mg/dL, though some included patients were found to carry the diagnosis of moderate-to-severe renal disease on evaluation of ICD-9 codes through CHCS. Thus, it is possible that patients with small body habitus and poor underlying kidney function could have been included based solely on their baseline SCr.
The results of this study were presented in a multidisciplinary educational meeting as well as a hospital-wide research competition to raise awareness of the increased rate of nephrotoxicity in combination therapy within Tripler Army Medical Center. The findings of increased nephrotoxicity with combination vancomycin and piperacillintazobactam were taken into consideration in the decision to add the fifth-generation cephalosporin ceftaroline to formulary at our institution for skin/soft-tissue infections. Also, these findings support the need for proper initial empiric antibiotic regimens and rapid tapering of broad-spectrum therapy within our military training facility.
CONCLUSION
Our retrospective study showed that there is a statistically significant difference in the incidence of nephrotoxicity when comparing patients who received vancomycin with piperacillintazobactam vs. vancomycin without piperacillin-tazobactam within our institution, even after accounting for comorbidities and other nephrotoxic agents. This finding influenced our institution's decision to add ceftaroline as a formulary agent in the treatment of skin and soft-tissue infections. Also, our findings supported the need for rapid de-escalation of antibiotics within our military training facility.
